SEC Comment Letter 0000000000-23-002178 to ZEVRA THERAPEUTICS, INC. (ZVRA)
ZEVRA THERAPEUTICS, INC.
Date: March 3, 2023 · CIK: 0001434647 · Accession: 0000000000-23-002178
AI Filing Summary & Sentiment
File numbers found in text: 001-36913
Letter
United States securities and exchange commission logo March 3, 2023 R. LaDuane Clifton Chief Financial Officer Zevra Therapeutics, Inc. 1180 Celebration Boulevard, Suite 103 Celebration, FL 34747 Re:Zevra Therapeutics, Inc. Preliminary Proxy Statement on Schedule 14A Filed February 27, 2023 File No. 001-36913 Dear R. LaDuane Clifton: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. All defined terms have the same meaning as in the proxy statement. Preliminary Proxy Statement on Schedule 14A filed February 27, 2023 When are stockholder proposals and director nominations due for next year's annual meeting?, page 10 1.Please provide the disclosure required by Rule 14a-5(e)(4). See Item 1(c) of Schedule 14A and Rule 14d-19(b). Annex A. Information Concerning Participants in the Company's Solicitation of Proxies, page A- 2.Please disclose the information required by Item 5(b)(1)(iii) of Schedule 14A, which requires you to disclose whether or not any of the specified individuals have been involved in any proceedings.
FirstName LastNameR. LaDuane Clifton Comapany NameZevra Therapeutics, Inc. March 3, 2023 Page 2 FirstName LastName R. LaDuane Clifton Zevra Therapeutics, Inc. March 3, 2023 Page 2 General 3.For proposals 2 and 3, please disclose the effect of an "ABSTAIN" vote. See Item 21(b) of Schedule 14A. We remind you that the filing persons are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please direct any questions to Michael Killoy at (202) 551-7576 or Christina Chalk at (202) 551-3263. Sincerely, Division of Corporation Finance Office of Mergers & Acquisitions
Show Raw Text
United States securities and exchange commission logo
March 3, 2023
R. LaDuane Clifton
Chief Financial Officer
Zevra Therapeutics, Inc.
1180 Celebration Boulevard, Suite 103
Celebration, FL 34747
Re:Zevra Therapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed February 27, 2023
File No. 001-36913
Dear R. LaDuane Clifton:
We have reviewed your filing and have the following comments. In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
Please respond to these comments by providing the requested information or advise us as
soon as possible when you will respond. If you do not believe our comments apply to your facts
and circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
All defined terms have the same meaning as in the proxy statement.
Preliminary Proxy Statement on Schedule 14A filed February 27, 2023
When are stockholder proposals and director nominations due for next year's annual meeting?,
page 10
1.Please provide the disclosure required by Rule 14a-5(e)(4). See Item 1(c) of Schedule
14A and Rule 14d-19(b).
Annex A. Information Concerning Participants in the Company's Solicitation of Proxies, page A-
1
2.Please disclose the information required by Item 5(b)(1)(iii) of Schedule 14A, which
requires you to disclose whether or not any of the specified individuals have been
involved in any proceedings.
FirstName LastNameR. LaDuane Clifton
Comapany NameZevra Therapeutics, Inc.
March 3, 2023 Page 2
FirstName LastName
R. LaDuane Clifton
Zevra Therapeutics, Inc.
March 3, 2023
Page 2
General
3.For proposals 2 and 3, please disclose the effect of an "ABSTAIN" vote. See Item 21(b)
of Schedule 14A.
We remind you that the filing persons are responsible for the accuracy and adequacy of
their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please direct any questions to Michael Killoy at (202) 551-7576 or Christina Chalk at
(202) 551-3263.
Sincerely,
Division of Corporation Finance
Office of Mergers & Acquisitions